Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals

Xue, Yingwei; He, Wenfu; Lü, Wan-Liang; Du, Ju; Guo, Jia; Tian, Wei; Men, Ying; Zhang, Yan; Li, Ruo‐Jing; Yang, Tingyuan; Shang, Dewei; Lou, Jinning; Zhang, Liangren; Zhang, Qiang

doi:10.1016/j.jconrel.2009.09.020

Cited by 408 publications

(231 citation statements)

References 50 publications

Supporting

Mentioning

219

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the TEER value of the coculture remained above 250 Ω cm 2 from the beginning to the end during the experiment, which indicated that the liposome transport did not violate the integrity of the BBB barrier. 43 As illustrated in Figure 3, the results showed that the uptake of GLU400-LIP, GLU1000-LIP, and GLU2000-LIP was more efficient than that of GLU200-LIP by the BBB in vitro, and the transendothelial abilities of the four types of glucose-modified liposomes were all much stronger than that of LIP, which is evidence that glucose-modification and longer PEGs could promote the liposome to transport across the BBB. The results also confirmed that PEGs with shorter chain length (PEG 200) may obstruct the exposure of the glucose.…”

mentioning

confidence: 85%

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting

Xie

Yao²,

Qin³

et al. 2012

IJN

116

View full text Add to dashboard Cite

Background An intimidating challenge to transporting drugs into the brain parenchyma is the presence of the blood–brain barrier (BBB). Glucose is an essential nutritional substance for brain function sustenance, which cannot be synthesized by the brain. Its transport primarily depends on the glucose transporters on the brain capillary endothelial cells. In this paper, the brain-targeted properties of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers were compared and evaluated to establish an optimized drug-delivery system. Methods Coumarin 6-loaded liposomes (GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-LIP) composed of phospholipids and glucose-derived cholesterols were prepared by thin-film dispersion-ultrasound method. The BBB model in vitro was developed to evaluate the transendothelial ability of the different liposomes crossing the BBB. The biodistribution of liposomes in the mice brains was identified by in vivo and ex vivo nearinfrared fluorescence imaging and confocal laser scanning microscopy and further analyzed quantitatively by high-performance liquid chromatography. Results Glucose-derived cholesterols were synthesized and identified, and coumarin 6-loaded liposomes were prepared successfully. The particle sizes of the four types of glucose-modified liposomes were around or smaller than 100 nm with a polydispersity index less than 0.300. GLU400-LIP, GLU1000-LIP, and GLU2000-LIP achieved higher cumulative cleared volumes on BBB model in vitro after 6 hours compared with GLU200-LIP ( P < 0.05) and were significantly higher than that of the conventional liposome ( P < 0.001). The qualitative and quantitative biodistribution results in the mice showed that the accumulation of GLU1000-LIP in the brain was the highest among all the groups ( P < 0.01 versus LIP). Conclusion The data indicated that GLU400-LIP, GLU1000-LIP, and GLU2000-LIP all possess the potential of brain targeting, among which GLU1000-LIP, as a promising drug-delivery system, exhibited the strongest brain delivery capacity.

show abstract

mentioning

confidence: 85%

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting

Xie

Yao²,

Qin³

et al. 2012

IJN

116

View full text Add to dashboard Cite

show abstract

“…This pH-sensitive release of DOX may be significant because of the acidic microenvironments found in tumor tissues and cell lysosomes. 36 The DL content of DOX in the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 was 20.1%±1.6%, which was less than that for the ACNP-DOX-DSPE-PEG2000 complex (29.8%±2.56%) and the ACNP-DOX complex (31.2%±2.64%), as shown in Table 1, which may be attributed to the increasing size of the complex, including the additional conjugated antibody.…”

mentioning

confidence: 88%

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

Jiang¹,

Wang²,

Zhang³

et al. 2016

IJN

View full text Add to dashboard Cite

“…The peptide angiopep-2 has also been attached onto the surface of several nanomedicines to target LRP1 [69,70]. Furthermore, glucose or mannose conjugation to nanomedicines has conferred brain-targeting properties through overexpressed facilitative glucose transporters [71,72].…”

Section: Systemic Delivery Of Nanomedicinesmentioning

confidence: 99%

Managing CNS Tumors: The Nanomedicine Approach

Aparicio-Blanco¹,

Torres-Suárez²

2017

New Approaches to the Management of Primary and Secondary CNS Tumors

View full text Add to dashboard Cite

Albeit the rapidly evolving knowledge about tumor biochemistry enables various new drug molecules to be designed as treatments, malignant central nervous system (CNS) tumors remain untreatable due to the failure to expose the entire tumor to such therapeutics at pharmacologically meaningful quantities. Therefore, drug delivery in CNS tumors must be properly addressed, as otherwise, novel therapies will continue to fail. In this regard, nanomedicine poses an appealing platform for efficient drug delivery to the CNS, since it may be targeted to improve the drug availability in the site of action, which would be translated into lower drug doses and fewer side effects. Hence, the accumulation of data about the CNS physiology and their relevant receptors, the widening therapeutic armamentarium of drugs potentially useful in CNS chemotherapy and the alternative routes for administration may envisage nanomedicines as a forthcoming routine approach. Indeed, on the basis of the promising results gathered from preclinical studies of nanomedicine-based therapy both systemically and locally administered, some nanomedicines have already been approved for clinical trials in a variety of CNS tumor conditions to serve as the first steps in the translation of nanotherapy to clinic. Their outcome will steer research directions for further improvements.

show abstract

Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals

Cited by 408 publications

References 50 publications

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

Managing CNS Tumors: The Nanomedicine Approach

Contact Info

Product

Resources

About